抗VEGF药物在视网膜血管性疾病围手术期的应用

血管内皮生长因子（VEGF）与新生血管性眼病密切相关,是有效的治疗靶点.抗VEGF药物能减少新生血管形成,降低血管通透性,为新生血管性眼病的治疗带来重大变革.目前雷珠单抗在国内已被批准用于湿性年龄相关性黄斑变性的治疗,在美国被批准用于糖尿病性黄斑水肿和视网膜静脉阻塞后黄斑水肿的治疗.抗VEGF药物也作为适应证外治疗药物用于其他新生血管性眼病的治疗,如增生性糖尿病视网膜病变、其他视网膜血管性疾病和新生血管性青光眼等.抗VEGF药物辅助手术治疗显示出明显的疗效,可减少术中、术后的并发症和疾病的复发率.就贝伐单抗和雷珠单抗等抗VEGF药物在视网膜血管性疾病围手术期的应用情况进行综述.

Application of anti-VEGF agents in the perioperative period of retinal vascular diseases

Vascular endothelial growth factor （VEGF） was proved to be closely associated with neovascularizational ocular diseases and a new therapeutic target.Anti-VEGF agents can inhibit the neovascularization and decrease the permeability of blood vessels.The application of anti-VEGF agents has revolutionized the treatment of these diseases.Ranibizumab has been approved to apply for the treatment of wAMD in China.In USA,it has been also approved to apply for the treatment of macular edema induced by diabetes or retinal vein occlusion.As off-label drug use,anti-VEGF agents also are used for other ocular neovascular diseases,such as proliferative diabetic retinopathy,other retinal vascular diseases and neovascular glaucoma.The clinical application of anti-VEGF agents as an adjunctive treatment modality to surgery has shown the obvious therapeutic effect,including minimizing the risk of complication and recrudescence in intraoperation and posteoperation.The perioperative research and application of anti-VEGF drugs including bevacizumab and ranibizumab in retinal vascular diseases were reviewed.